#USA #biotechnology #Providence #EpiVax #Immunogenicity

EpiVax's Remarkable Journey in Immunogenicity for 2024

In 2024, EpiVax, Inc. established itself as a noteworthy player in the realm of immunogenicity risk assessment for biologic and peptide therapeutics. With substantial scientific innovations, diversification of its services, and impressive company growth, EpiVax has set new benchmarks in the industry.

Expanding Services and Toolkit Innovations

This year, EpiVax significantly broadened its service offerings in immunogenicity risk evaluation. They introduced multiple new capabilities within their ISPRI™ Toolkit (Immunogenicity Screening and Protein Re-engineering Interface). These enhancements included the launch of several fee-for-service analyses like ISPRI Downselect™, Quantify™, Analyze™, Evaluate™, Complete™, Optimize™, and Design™. These options cater to various stages of preclinical development, enabling precise sequence optimization, risk analysis, and candidate comparison.

Furthermore, EpiVax introduced Class I analysis to its ISPRI toolkit, benefiting clients involved in gene and cell therapy, thus reinforcing its reputation as a leader in providing tailored immunogenicity insights.

Advancements in PANDA® Screening Program

EpiVax also made notable strides with its PANDA® Screening program. This initiative supports sponsors on their pathway to securing abbreviated new drug applications (ANDA) from the FDA, particularly focusing on generic peptides and their impurities. Enhanced in vitro adaptive testing and innate immune response assays were key updates for PANDA®, establishing EpiVax as a one-stop solution for generic drug developers, incorporating assessments across in silico, in vitro, and innate immune responses.

Moreover, the company partnered with the FDA to standardize controls for T-cell assays, aiming to enhance the specificity and sensitivity of these tests across the industry—a landmark move that underscores EpiVax's forward-thinking approach.

Growth and Success Metrics

Thanks to its diversified services, EpiVax’s bookings for immunogenicity risk evaluations surged nearly 60% compared to 2023, showcasing an impressive doubling of its client base in verticals such as ISPRI™ Access, ISPRI™ Fee-for-Service, and PANDA®. This success facilitated an 18% increase in workforce numbers, including the recruitment of strategic leaders to further propel the development of the company's new offerings.

Future Directions for 2025

Looking ahead to 2025, EpiVax aims to leverage its nearly thirty years of unyielding scientific exploration. The company is set to integrate more artificial intelligence and machine learning enhancements into its existing platforms, as well as expand its laboratory capabilities and scientific expertise, with announcements planned for the upcoming year.

About EpiVax

EpiVax is recognized for its preclinical immunogenicity assessments and sequence optimization for peptide therapies, biological therapies, and vaccines. Collaborating with companies, regulatory agencies, and academic institutions globally, EpiVax is committed to fast-tracking immunogenicity risk evaluation and vaccine design.

For more details, visit www.epivax.com.